Background: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectable or borderline resectable pancreatic cancer.
Introduction
Pancreatic cancer is recognized as having an overall poor prognosis and low resection rate. Long-term survival remains limited even after tumour resection. Surgical resection with adjuvant chemotherapy is the current standard of care 1 . Recent trials 1,2 have reported improved median overall survival to 24⋅5-28 months with adjuvant treatment. However, these trials did not report how many eligible patients were fit enough to be randomized to receive adjuvant chemotherapy. Currently, the strongest predictors of survival include surgery with curative intent, early-stage disease and complete (R0) resection 3, 4 . None of these predictors are influenced by adjuvant treatment.
In patients with resectable pancreatic cancer, a recent study 5 of Surveillance, Epidemiology, and End Results (SEER) data from nearly 4000 patients suggested a survival benefit with neoadjuvant radiotherapy with or without chemotherapy over upfront surgery with or without adjuvant treatment. However, RCTs of neoadjuvant treatment compared with upfront surgery are lacking.
Non-randomized studies evaluating neoadjuvant treatment of patients with either borderline resectable or upfront resectable pancreatic cancer often suffer from selection bias because they report survival data only for patients who eventually underwent pancreatic resection. Patients with disease progression or severe toxicity who did not undergo resection are often excluded. Moreover, patients found to have metastatic or unresectable disease at exploratory surgery are also excluded 5, 6 .
The aim of this study was to perform a systematic review of studies comparing median overall survival of patients who underwent upfront surgery versus those who underwent neoadjuvant treatment in intention-to-treat analyses.
Methods
The systematic review was performed according to the PRISMA guidelines 7 . The review was registered at PROS-PERO (registration number: CRD42016049374).
Search strategy
The literature was reviewed systematically by searching in MEDLINE, Embase and the Cochrane Library for studies published between 1 January 2000 and 6 December 2016. The search strategy included the following domains of Medical Subject Heading (MeSH) terms: 'pancreatic neoplasm', 'survival', 'mortality' and 'survival analysis'; these were combined with 'AND' or 'OR'. No language restrictions were used. For the MEDLINE and Embase searches, a McMaster specific prognosis filter was applied, completed with the authors' own terminology to cover the survival concept of the search strategy. A full description of the search is available in Appendix S1 (supporting information).
Eligibility
Studies including patients with resectable or borderline resectable pancreatic cancer, either treated by upfront surgery or with neoadjuvant treatment, and reporting median overall survival by intention to treat (based on the initial treatment assignment and not on the treatment eventually received) were included. No selection was made based on adjuvant treatment. Excluded were review articles, notes, letters, case reports (5 or fewer patients), animal studies, studies that did not report median overall survival by intention to treat, and studies that reported on only specific groups of patients (for example, those with renal impairment, older than 70 years, or with poor performance status). Studies that did not report median overall survival separately for resectable and borderline resectable pancreatic tumours were also excluded.
Study selection
Two authors screened the titles and abstracts independently for eligibility. After the first two rounds of screening, full-text screening was carried out. Disagreements were resolved by discussion and consensus achieved. Primary and secondary outcomes were extracted from the full text. If studies had an overlapping cohort, the most recent study was included.
Methodological quality
All studies were assessed for risk of bias using a standard list of 11 potential risks of bias, based on the Oxford Centre for Evidence-Based Medicine (CEBM) Critical Appraisal Skills Programme checklists for randomized trials and observational cohort studies, and the Cochrane Collaboration's tool for assessing risk of bias 8 -11 . All studies were graded according to the Oxford CEBM levels of evidence 12 .
Outcome measures
The primary outcome, median overall survival, was extracted from the included articles. Data on numbers of patients with (borderline) resectable pancreatic cancer, resectability criteria (for example, those of the National Comprehensive Cancer Network (NCCN) and American Hepato-Pancreato-Biliary Association (AHPBA)), and types of neoadjuvant treatment and adjuvant treatment were obtained. Secondary outcomes were: resection rate, completeness of resection (R0 resection rate, only for patients undergoing resection), pathological lymph node rate, reasons for unresectability, and toxicity of at least grade III after neoadjuvant treatment.
Statistical analyses
The weighted median overall survival was calculated for the studies reporting this information for groups with and without neoadjuvant treatment. The weighted estimate of median survival (m p ) of both groups was derived by the formula used by Gillen and colleagues 13 in a previous systematic review:
where m i denotes the median survival in a study population i (with i ranging from 1 to k, where k is the number of included studies) and w i refers to a study-specific weight function. The number of study participants (divided by the total number of evaluable patients) was used as the weight. The overall resection rate and the R0 rate for both groups were also calculated. The R0 rate was calculated for all patients and also for those who actually underwent resection of the pancreatic cancer. For both the overall resection rate and the R0 rate, the 95 per cent confidence interval was calculated using a proportion calculator 14 . The significance of differences in proportions was assessed by means of two-tailed Fisher's exact test, with a significance level α = 0⋅050, using SPSS ® version 22.0.0.2 (IBM, Armonk, New York, USA).
Results
A total of 18 828 records were identified, of which 122 screened were fully. Finally, 38 studies 15 -52 were included, with 3484 patients (Fig. 1) . Study characteristics are summarized in Tables 1 and 2 . Three RCTs, nine phase I or II trials, 12 prospective cohort studies and 14 retrospective cohort studies were included. The range of median age was 61⋅9-69⋅0 years in the upfront surgery group and 59-73 years in the neoadjuvant group (Tables 3 and 4) . Overall, neoadjuvant treatment was administered to 1723 of 1738 patients (99⋅1 per cent). All studies used at least chemotherapy as neoadjuvant treatment, usually including gemcitabine (26 of 35 studies). Radiotherapy was given as part of the neoadjuvant treatment in 29 of 35 studies. No study used radiotherapy as the sole neoadjuvant treatment. The radiation dose ranged from 30 to 54 Gy.
Adjuvant therapy was initiated in ten of 12 upfront surgery studies, and 68⋅6 per cent of patients who underwent resection started adjuvant treatment. In the neoadjuvant treatment group, adjuvant therapy was initiated in 18 of 35 studies, and 31 per cent of patients who had resection of the pancreatic tumour started adjuvant therapy. Fewer studies reported the numbers of patients who completed adjuvant therapy (Tables 1 and 2 ).
Methodological quality
Results of the methodological quality assessment of all studies are reported in Tables S1-S3 (supporting information). Most studies were retrospective (14) or 16 33 Germany RCT R n.s. 44 n.r. Bao et al. 17 78 USA Prospective R n.s. 78 n.r. Raptis et al. 18 102 UK Prospective R n.r. n.r. n.r. Tzeng et al. 19 52 USA Prospective R n.s. n.r. 60 Fujii et al. 20 71 Japan Prospective BR > 1 100 42 Fujii et al. 21 233 Japan Prospective R > 1 6 9 4 5 ⋅6 Barbier et al. 22 85 France Retrospective R > 1 5 8 n . r . Papalevoza et al. 23 92 USA Retrospective R n.s. Adjuvant CRT: 66 n.r. Kato et al. 24 624 Japan Retrospective BR n.s. 78⋅7 n . r . Adjuvant CT only: 69⋅9 Hirono et al. 25 331 Japan Retrospective R + BR 0 BR-A: 84⋅5 7 6 Murakami et al. 26 25 Japan Retrospective BR n.s. 48 n.r.
*Definition of R0: > 1, more than 1 mm clearance from each margin; 0, no cancer cells along any margin. †Among patients who underwent resection of pancreatic cancer. R, resectable; n.r., not reported; n.s., not specified; prospective, prospective cohort study; BR, borderline resectable; retrospective, retrospective cohort study; CRT, chemoradiotherapy; CT, chemotherapy; BR-A, borderline resectable with arterial involvement. Palmer et al. 27 50 UK RCT R n.s. CT n.r. n.r. Casadei et al. 15 18 Italy RCT R > 1 CRT 75 n.r. Golcher et al. 16 33 Germany RCT R n.s. CRT 37 n.r. Evans et al. 28 86 USA Phase II R 0 CRT n.r. n.r. Heinrich et al. 29 28 Switzerland Phase II R n.s. CT n.r. n.r. Le Scodan et al. 30 41 France Phase II R n.s. CRT n.r. n.r. Turrini et al. 31 34 France Phase II R 0 CRT n.r. n.r. Small et al. 32 17 USA Phase II R + BR n.s. CRT n.r. n.r. Esnaola et al. 33 13 USA Phase II BR n.s. Mixed n.r. n.r. Kim et al. 34 62 USA Phase II R + BR n.s. CRT 63 92 O'Reilly et al. 35 38 USA Phase II R n.s. CT 96 89 Shaib et al. 36 13 USA Phase I BR n.s. CRT n.r. n.r. Calvo et al. 37 15 Spain Prospective R n.s. CRT n.r. n.r. Ohigashi et al. 38 38 Korea Prospective BR n.s. CRT 100 100 Katz et al. 39 22 USA Prospective BR 0 CRT 67 90 Oh et al. 40 38 Korea Prospective BR n.s. CRT 61 n.r. Tzeng et al. 41 141 USA Prospective BR n.s. CRT n.r. n.r. Tzeng et al. 19 115 USA Prospective R n.s. CRT 7⋅8 n . r . Fujii et al. 20 21 Japan Prospective BR > 1 CRT 100 56 Fujii et al. 21 40 Japan Prospective R > 1 CRT 83 56 Ielpo et al. 42 11 Spain Prospective BR n.s. CT 100 n.r. Masui et al. 43 18 Japan Prospective BR > 1 C T 9 3 n . r . Takai et al. 44 32 Japan Retrospective R n.s. CRT n.r. n.r. Barbier et al. 22 88 France Retrospective R > 1 CRT n.r. n.r. Patel et al. 45 18 USA Retrospective BR 0 CRT n.r. n.r. Papalevoza et al. 23 144 USA Retrospective R n.s. CRT 32⋅9 n . r . Chuong et al. 46 57 USA Retrospective BR 0 CRT 84 n.r. Dholakia et al. 47 50 USA Retrospective BR 0 CRT 42 n.r. Boone et al. 48 61 USA Retrospective R + BR n.s. Mixed n.r. n.r. Rose et al. 49 64 USA Retrospective BR > 1 C T / C R T 9 0 n . r . Moningi et al. 50 14 USA Retrospective BR n.s. CRT n.r. n.r. Sho et al. 51 99 Japan Retrospective R + BR n.s. CT/CRT n.r. R: 75 BR-V: 49 BR-A: 31 Rashid et al. 52 121 USA Retrospective BR 0 CRT n.r. n.r. Hirono et al. 25 46 Japan Retrospective BR 0 Mixed 85 61 Murakami et al. 26 52 Japan Retrospective BR n.s. CT 79 n.r.
*Definition of R0: > 1, more than 1 mm clearance from each margin; 0, no cancer cells along any margin. †Among patients who underwent resection of pancreatic cancer. R, resectable; n.r., not reported; n.s., not specified; CT, chemotherapy; CRT, chemoradiotherapy; BR, borderline resectable; prospective, prospective cohort study; retrospective, retrospective cohort study; BR-V, borderline resectable with venous involvement; BR-A, borderline resectable with arterial involvement. prospective (12) cohort studies. The studies showed heterogeneity in treatment and potential bias in collecting data. A common risk of bias was the heterogeneity of neoadjuvant and adjuvant treatments within and between the studies. Furthermore, there was wide variation in the duration of follow-up; in eight studies the follow-up was shorter than 12 months. In addition, different criteria were used for resectability, although most studies used the NCCN guidelines. Three RCTs were included, one 27 of which randomized between neoadjuvant gemcitabine or gemcitabine combined with capecitabine in patients with resectable pancreatic cancer. The other two trials 15, 16 randomized between neoadjuvant chemoradiotherapy and upfront surgery, but both were terminated early owing to poor accrual.
Primary outcome
The weighted median overall survival by intention to treat was 18⋅8 months in the neoadjuvant group and 14⋅8 months in the upfront surgery group.
Upfront surgery
Twelve studies 15 -26 reported the median overall survival of 1746 patients undergoing upfront surgery for resectable or borderline resectable pancreatic cancer by intention to treat (Figs 2 and 3) . Overall, 81⋅3 per cent of 1746 patients underwent resection, with an overall weighted median overall survival of 14⋅8 (range 11⋅6-25⋅3) months.
The weighted median overall survival of 819 patients with resectable pancreatic cancer was 17⋅7 (12-25⋅3) months 15 Figs 2 and 3) . In the largest (retrospective) study of Kato and colleagues 24 , 63 of 624 patients (10⋅1 per cent) with borderline resectable pancreatic cancer also received neoadjuvant treatment and the median overall survival of these patients was not available separately. The outcome of the subgroup of patients who actually underwent resection was reported in seven 16, 18, 22 -26 of 12 studies; the weighted median overall survival was 15⋅0 months for these 1048 patients (not by intention to treat).
Neoadjuvant treatment
Thirty-five studies 15, 16, 19 -23,25-52 reported median overall survival after neoadjuvant treatment of 1738 patients with resectable or borderline resectable pancreatic cancer. The neoadjuvant regimens used are shown in Table 2 . The weighted median overall survival was 18⋅8 (range 9⋅4-50⋅2) months after neoadjuvant treatment.
For the 18 studies 15,16,19,21 -23,27-32,34,35,37,44,48,51 that reported the median overall survival of 857 patients with resectable pancreatic cancer, the weighted median overall survival was 18⋅2 (10-50⋅2) months (Fig. 2) . In the 21 studies 20,25,26,32 -34,36,38-43,45-52 reporting the median overall survival after neoadjuvant treatment in 881 patients with borderline resectable cancer, the weighted median overall survival was 19⋅2 (11-32) months (Fig. 3) .
The outcome for the subgroup of patients who actually underwent resection was reported in 19 
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Prospective cohort study Retrospective study Phase I or II study Fig. 2 Median overall survival, with 95 per cent confidence intervals, for patients with resectable pancreatic cancer after upfront surgery and after neoadjuvant treatment. The square of radius of the spheres is related to number of patients in the study
Secondary outcomes

Resection rate and R0 rate
The overall resection rate was lower in patients who had neoadjuvant treatment than in those who had upfront surgery (66⋅0 versus 81⋅3 per cent; P < 0⋅001). After upfront surgery, the resection rate in all 1746 patients was 81⋅3 (95 per cent c.i. 79⋅4 to 81⋅3) (range 32⋅7-92) per cent. For patients with resectable pancreatic cancer, the resection rate was 76⋅8 (95 per cent c.i. 73⋅8 to 79⋅7) per cent, compared with 85⋅3 (82⋅9 to 87⋅5) per cent for those with borderline resectable pancreatic cancer (P < 0⋅001).
For patients who received neoadjuvant treatment, the resection rate was reported in 35 studies 15, 16, 20 -23,25-52 and was 66⋅0 (95 per cent c.i. 63⋅7 to 68⋅2) (range 29-100) per cent. For patients with resectable pancreatic cancer, the resection rate was 67⋅0 (95 per cent c.i. 63⋅7 to 70⋅1) per cent, compared with 65⋅0 (61⋅8 to 68⋅2) per cent for those with borderline resectable pancreatic cancer (P = 0⋅418). The resection rate for patients in the neoadjuvant group who underwent an exploratory laparotomy was 91⋅2 per cent.
The R0 resection rate (only for patients who underwent resection) was higher in patients who had neoadjuvant treatment (86⋅8 versus 66⋅9 per cent; P < 0⋅001). The R0 resection rate was also higher with neoadjuvant treatment when the results were reported by intention to treat (58⋅0 versus 54⋅9 per cent; P = 0⋅088). This difference is obviously smaller, because it is the resection rate multiplied by the R0 rate.
The R0 resection rate was reported in 11 studies 15 -17,19-26 after upfront surgery and was 66⋅9 (95 per cent c.i. 64⋅2 to 69⋅6) (range 17-81) per cent. After upfront surgery, the R0 resection rate was 71⋅4 per cent for patients with resectable pancreatic cancer, and 63⋅9 per cent for those with borderline resectable pancreatic cancer. For patients treated with neoadjuvant therapy who underwent exploratory laparotomy followed by resection, the R0 resection rate was 86⋅8 (95 per cent c.i. 84⋅6 to 88⋅7) (range 38⋅9-100) per cent. After neoadjuvant treatment, the R0 resection rate was 85⋅0 per cent among patients
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Pathological lymph node rate
The pathological lymph node rate was reported in 11 studies 15 . This difference in pathological lymph node rates between the two groups was significant (P < 0⋅001).
Reasons for not performing surgery
Of the 35 neoadjuvant therapy studies, 29 reported the reason for not performing exploratory surgery. In total, 306 patients (17⋅8 per cent) did not proceed to exploratory surgery. Progression of disease (locally advanced or metastasis) was the most common reason for not undertaking exploratory surgery in 64⋅4 per cent of these patients. In total, 55 patients (18⋅0 per cent) could not undergo surgery because of severe side-effects or deterioration of performance after neoadjuvant treatment, representing 3⋅2 per cent of all patients starting neoadjuvant treatment. For the remaining patients there were other reasons, or the reason was not known. The reasons for not performing tumour resection during exploratory surgery were reported in 23 of the 35 studies (Table S4 , supporting information). Resection was not undertaken in at least 532 patients (15⋅3 per cent of all 3484 included patients). The most common reason for this was distant metastasis in 42⋅5 per cent of these patients. Disease progression was the reason for not resecting the tumour in 25⋅6 per cent.
Toxicity
There was a wide range of reported toxicity of neoadjuvant treatment across studies. The most common reported adverse events were gastrointestinal (emesis, nausea and diarrhoea) and haematological (thrombopenia, leucopenia 39 reported a grade III toxicity rate of 64 per cent, in a study in which FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan and oxaliplatin) chemotherapy was combined with radiotherapy at a dose of 50⋅4 Gy. Grade IV toxicity was reported in 13 studies, and consisted mostly of haematological adverse events.
Discussion
In this systematic review, median overall survival was 18⋅8 months after neoadjuvant treatment versus 14⋅8 months after upfront surgery of resectable or borderline pancreatic cancer in intention-to-treat analysis. The R0 resection rate and pathological lymph node rate were also improved in the neoadjuvant group. These results suggest the superiority of neoadjuvant treatment over upfront surgery. Previous studies 13, 53 reported outcomes of patients who actually underwent resection, rather than reporting by intention to treat, thus introducing a survival bias.
Median survival times for patients who actually underwent resection were 26⋅1 months in the neoadjuvant group and 15⋅0 months for upfront surgery in this review. This difference in median overall survival between the groups (11⋅1 months) is much bigger than the difference in the intention-to-treat analysis (4⋅0 months). Reporting by intention to treat reduces potential bias in treatment effect as not all patients proceed to surgery, and a large proportion of patients do not receive adjuvant chemotherapy owing to postoperative complications. Prospective phase II studies investigating the role of neoadjuvant treatment have to report on all patients included in the trial by intention to treat 54 . Therefore, for a fair comparison, upfront surgery studies and observational studies of neoadjuvant treatment should also report by intention to treat.
In the present review, 17⋅8 per cent of patients who had neoadjuvant treatment did not undergo exploratory surgery. This selects out patients with an aggressive pancreatic cancer that would probably have progressed in a short time after surgery anyway, thus avoiding a potentially harmful operation. In the upfront surgery group, the resection rate for patients with borderline resectable pancreatic cancer was significantly higher than that for patients with resectable tumours (85⋅3 versus 76⋅8 per cent respectively). This is a counterintuitive finding, as one would expect the resection rate to be higher for resectable pancreatic cancer. There is no good explanation for this finding, but the different criteria being used worldwide for assessing resectability or suboptimal preoperative assessment on CT may play a role. Centralization of pancreatic surgery has led to increased resection rates 55 , but this was not investigated here.
The R0 resection rate among patients actually undergoing tumour resection was significantly better in the neoadjuvant treatment group, which is in line with the hypothesis that neoadjuvant treatment provides higher R0 rates than surgery alone 56 . The R0 resection rate after upfront surgery is comparable to rates of 29-81 per cent, depending on the R0 criteria being used, in recent large series of pancreatic cancer resection 1, 57, 58 . The pathological lymph node rate was also significantly different between the upfront surgery and neoadjuvant treatment groups, which may be the result of the neoadjuvant treatment causing regression of lymph node metastases 59 .
No difference in surgical morbidity and mortality has been reported in studies comparing neoadjuvant treatment with upfront surgery 60 -62 . A possible advantage of neoadjuvant radiation is the development of pancreatic fibrosis, which may be associated with reduced occurrence of pancreas fistula after resection 60, 61, 63 . Adjuvant chemotherapy is the current standard of care after resection of pancreatic cancer 1 , but this treatment is often not given, or not completed, owing to a prolonged complicated postoperative course, or the preference of the patient or doctor. Data from the Netherlands Cancer Registry 64 revealed that only 54 per cent of all patients undergoing pancreatoduodenectomy received adjuvant chemotherapy, because of toxicity, age and other factors. In the present review, the toxicity reported most frequently consisted of adverse gastrointestinal and haematological events. Overall, treatment-related toxicity was given as the reason for not proceeding to exploratory surgery in only 3⋅2 per cent of the 1723 patients who started neoadjuvant treatment.
Median overall survival varied widely across the studies, which may be explained by the different criteria used for resectability. Most studies used the NCCN or MD Anderson Cancer Center criteria for resectability 65, 66 , but some studies used neither of these. Objective definitions of resectability are critical for the conduct of clinical trials of neoadjuvant treatment. Another explanation for the heterogeneity may be the variation in neoadjuvant treatment regimens across studies. The difference in receipt of postoperative adjuvant treatment (68⋅6 per cent in the upfront surgery group versus 31 per cent in the neoadjuvant group) may in part be explained by the fact that these patients had already received part or all of their systemic therapy before surgery.
The expert consensus statement of the AHPBA 67 indicates that neoadjuvant therapy provides a rational alternative to an upfront surgery approach and could be considered in all patients with resectable pancreatic cancer. Evidence from RCTs is still lacking. The Dutch Pancreatic Cancer Group has just finished accrual of the multicentre randomized PREOPANC trial (EU Clinical Trials Register: 2012-003181-40) of neoadjuvant chemoradiotherapy versus upfront surgery 68 . The hypothesis is that neoadjuvant chemoradiotherapy may result in an increase in R0 resection rate and overall survival in patients with resectable or borderline resectable pancreatic cancer 68 . The trial has randomized the required 248 patients during a 4-year interval and the first results are expected in 2018. Five other randomized trials 69 -73 are ongoing in Germany, Switzerland and Norway to investigate the role of neoadjuvant treatment in resectable pancreatic cancer. Two previous RCTs 15, 16 from Italy and Germany were terminated early because of poor accrual.
Some limitations of the present systematic review must be taken into account. First, the quality of the included studies is moderate; the majority are retrospective studies, with high suspicion of bias. Only three studies were RCTs, and only two of these, with a total of 104 patients, randomized between upfront surgery and neoadjuvant treatment followed by surgery. Both these studies were terminated early. Owing to the clinical and methodological heterogeneity, no network analysis could be performed. Despite the limitations, the results provide the most reliable survival data, reported by intention to treat, in patients with resectable or borderline resectable pancreatic cancer.
